BRCA1 genetic variant to predict survival in metastatic colorectal cancer (mCRC) patients (pts) treated with FOLFIRI/bevacizumab (bev): Results from phase III TRIBE and FIRE-3 trials. Background: ...
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Biomea Fusion, Inc., a precision oncology company dedicated to developing innovative medicines targeting genomically defined alterations in both hematologic and ...
Capecitabine (X) is resource saving compared with i.v. bolus 5-FU/LV in adjuvant chemotherapy for Dukes' C colon cancer patients: Medical resource utilization (MRU) data from a large phase III trial ...
Among patients with idiopathic pulmonary fibrosis, the risk for all-cause mortality was significantly lower with vs. without ...
Enzymatic cyclization of the linear polyketide chain to form a macrolactone is a key step in the biosynthesis of type I polyketide natural products. Structural biology and inhibitor design were used ...
At the Albert Einstein College of Medicine, Evripidis Gavathiotis, PhD, and colleagues have been developing inhibitors of Bcl-2-associated X protein (BAX), a molecule known to stimulate apoptosis. In ...
A research team at the University of Miami Miller School of Medicine's Center for Therapeutic Innovation (CTI) has identified a novel epigenetic drug target to simultaneously normalize multiple ...
Scientists at the University of Texas MD Anderson Cancer Center say have discovered a novel function for the metabolic enzyme medium-chain acyl-CoA dehydrogenase (MCAD) in glioblastoma (GBM). MCAD ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback